Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-15T17:29:15.989Z Has data issue: false hasContentIssue false
  • English
  • Français

The Effects of Risperidone vs Haloperidol on Cognitive Functioning in Treatment-Resistant Schizophrenia: The Trail Making Test

Published online by Cambridge University Press:  07 November 2014

Susan R. Mcgurk ,
Michael F. Green ,
William C. Wirshing ,
Donna Ames ,
B.D. Marshall Jr ,
Steven R. Marder  and
Jim Mintz
Get access Rights & Permissions [Opens in a new window]

Abstract

In this article, data are presented from Parts A and B of the Trail Making Test, which examined the effects of haloperidol vs risperidone on cognitive function in treatment-resistant scxhizophrenic patients. This report focuses on findings from the Trail Making Test. Overall, risperidone had a positive effect on Trail Making Part B performance following 4 weeks of treatment. These effects were due, at least in part, to the direct effects of risperidone. The possibility that an antipsychotic agent can enhance executive functioning through direct mechanisms, perhaps mediated by frontal cortex neurochemistry, indicates that the evaluation of antipsychotic medications in the treatment of schizophrenia should be expanded to include cognition.

Type
Feature Article
Information
CNS Spectrums , Volume 2 , Issue 8: The Maze of Cognitive Dysfunction , September 1997 , pp. 60 - 64
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Goldberg, TE, Berman, KF, Weinberger, DR. Neuropsychology and neurophysiology of schizophrenia. Curr Opin Psychiatry. 1995;8:34–40.CrossRefGoogle Scholar
2.Saykin, AJ, Schtasel, DL, Gur, RE, et al.Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994:51:124–131.CrossRefGoogle ScholarPubMed
3.Cassens, G, Inglis, AK, Appelbaum, PS, Gutheil, TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenia patients. Schizophr Bull. 1990:16:477–499.Google Scholar
4.Spohn, HE, Strauss, ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989:98:367–380.CrossRefGoogle ScholarPubMed
5.Bersani, G, Bressa, GM, Meco, G, Marinis, S, Pozzi, F. Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone. Hum Psychopharmacol. 1990:5:225–231.Google Scholar
6.Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994:151:825–835.Google Scholar
7.Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry. 1996:153:321–330.Google Scholar
8.Green, MF, Marshall, BD, Wirshing, WC, et al.Does risperidone improve verbal working memory in treatment-resistant schizophrenia?Am J Psychiatry. 1997; In press.Google Scholar
9.Trestman, RL, Keefe, RS, Mitropoulou, V, et al.Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res. 1995:58:127–136.CrossRefGoogle Scholar
10.Fredericks, RS, Finkel, P. Schizophrenic performance on the Halstead-Reitan Battery. J Clin Psychol. 1978:34:26–30.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed
11.Simon, SH. The effects of tranquilizers on the Trail Making Test with chronic schizophrenic patients. Journal ol Consulting Psychology (J Consult Clin Psychcol). 1967:31:322–323.Google Scholar
12.Kane, J, Honigfeld, G, Singer, J, Meltzer, H, Group, CCS. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988:45:789–796.Google Scholar
13.Altman, HJ, Normile, HJ. What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. Neurobiol Aging. 1988:9:627–638.Google Scholar